Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study

OBJECTIVE: Primary tumour location is regarded as a reliable surrogate of colorectal cancer biology. Sensitivity to anti-EGFRs (Epidermal Growth Factor Receptor) of metastatic transverse colon cancers (mTCCs) has usually been assumed similar to right-sided tumours; however, evidence about the clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Cremolini, Chiara, Benelli, Matteo, Fontana, Elisa, Pagani, Filippo, Rossini, Daniele, Fucà, Giovanni, Busico, Adele, Conca, Elena, Di Donato, Samantha, Loupakis, Fotios, Schirripa, Marta, Lonardi, Sara, Borelli, Beatrice, Ongaro, Elena, Eason, Katherine, Morano, Federica, Casagrande, Mariaelena, Fassan, Matteo, Sadanandam, Anguraj, de Braud, Filippo, Falcone, Alfredo, Pietrantonio, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435314/
https://www.ncbi.nlm.nih.gov/pubmed/30962964
http://dx.doi.org/10.1136/esmoopen-2019-000489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435314/
https://www.ncbi.nlm.nih.gov/pubmed/30962964
http://dx.doi.org/10.1136/esmoopen-2019-000489

Ejemplares similares